21Mar 2023
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16‐positive oropharynx cancer

Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16‐positive oropharynx cancer

The study investigated the early changes in CD8+ tumor-infiltrating lymphocytes and tumor transcriptomes after induction of cetuximab in patients with p16-positive oropharyngeal cancer. Tumor biopsies were taken before and one week after a single cetuximab loading dose in eight patients enrolled in a phase II trial. Results showed that cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content within one week. Five patients had an increase in CD8+ cell infiltration, while two patients showed rapid tumor transcriptome changes in cellular type 1 interferon signaling and keratinization pathways.

  • #ent

Like

Save

Share